Which Diseases Count as Spondyloarthropathies? A No‑Nonsense Guide
Ever flipped through a rheumatology brochure and stared at a list of tongue‑twisting names—ankylosing spondylitis, psoriatic arthritis, reactive arthritis—wondering if they’re all part of the same club? You’re not alone. In the clinic, patients often hear “spondyloarthropathy” tossed around and think it’s just a fancy way of saying “back pain.” The short version is: it’s a family of inflammatory joint diseases that share a genetic fingerprint, a tendency to involve the spine, and a few quirky extra‑articular tricks.
Below is the only guide you’ll need to separate the wheat from the chaff, spot the red flags, and walk away knowing exactly which conditions wear the spondyloarthropathy badge Easy to understand, harder to ignore. Still holds up..
What Is a Spondyloarthropathy?
When doctors say “spondyloarthropathy,” they’re not naming a single disease. Think of it as a genre—like “thriller” in movies—where each title has its own plot but follows the same basic formula Worth keeping that in mind..
At its core, a spondyloarthropathy (often shortened to SpA) is an inflammatory arthritis that:
- Targets the axial skeleton—the spine and sacroiliac joints—early on.
- Can spill over into peripheral joints (knees, ankles, elbows) and entheses (where tendons and ligaments attach to bone).
- Shows a strong link to the HLA‑B27 gene—about 80 % of patients carry it, though not everyone with the gene gets sick.
- Brings extra‑articular features—skin, eyes, gut, even the heart—into the mix.
The “SpA Spectrum”
The International Society for the Study of the Knee (ISSK) and the Assessment of SpondyloArthritis International Society (ASAS) have settled on a core list of diseases that belong in this family:
- Ankylosing Spondylitis (AS)
- Psoriatic Arthritis (PsA)
- Reactive Arthritis (ReA)
- Enteropathic Arthritis (associated with IBD)
- Undifferentiated Spondyloarthropathy (uSpA)
Anything outside that lineup—like rheumatoid arthritis or gout—doesn’t wear the SpA label, even if it hits the spine.
Why It Matters
Knowing whether a patient’s joint pain falls under the SpA umbrella changes everything:
- Treatment pathways diverge. Biologics that block IL‑17 or TNF‑α work wonders for SpA but are less effective for other arthritides.
- Prognosis shifts. Early detection of axial involvement can prevent irreversible spinal fusion.
- Screening expands. If you diagnose PsA, you’ll start looking for skin lesions; with enteropathic arthritis, you’ll ask about bowel habits.
Miss the classification and you risk overtreating or, worse, leaving a ticking time bomb of chronic inflammation to fester Turns out it matters..
How It Works: The Mechanics Behind the Classification
Let’s break down the criteria doctors use to decide, step by step.
1. Clinical Presentation
- Back pain that improves with exercise and worsens at night—classic for axial SpA.
- Peripheral arthritis that’s asymmetric (think one knee, the other ankle).
- Enthesitis—pain at the heel or the side of the rib cage where tendons attach.
If you hear “pain that eases when I move,” flag it for SpA.
2. Imaging
- X‑ray: Look for sacroiliitis (joint space narrowing, sclerosis) in the pelvis.
- MRI: Picks up early inflammation before bone damage shows on X‑ray.
- Ultrasound: Great for spotting enthesitis in the heel or forearm.
Radiologists will often mention “BME” (bone marrow edema) as a red flag for active SpA Most people skip this — try not to..
3. Laboratory Markers
- HLA‑B27: Positive in most axial cases, but a negative test doesn’t rule it out.
- CRP/ESR: Elevated inflammatory markers, though they can be normal in early disease.
4. Extra‑Articular Features
- Uveitis: Red, painful eye—common in AS and PsA.
- Psoriasis: Scaly plaques on elbows, scalp, or nails point to PsA.
- Inflammatory Bowel Disease: Crohn’s or ulcerative colitis often precede enteropathic arthritis.
5. ASAS Classification Criteria
For axial SpA, you need either:
- Imaging + ≥1 SpA feature (e.g., HLA‑B27, inflammatory back pain)
- HLA‑B27 + ≥2 SpA features
For peripheral SpA, the rule is a bit looser: arthritis, enthesitis, or dactylitis plus at least one of the following—uveitis, psoriasis, IBD, preceding infection, or HLA‑B27.
Which Diseases Are Actually Classified as Spondyloarthropathies?
Below is the definitive roll‑call, with the quirks that set each one apart.
Ankylosing Spondylitis (AS)
- The poster child of axial SpA.
- Starts in the sacroiliac joints, then climbs up the spine, eventually “bamboo‑spining” the vertebrae.
- Key clue: Morning stiffness >30 minutes that improves with activity.
Psoriatic Arthritis (PsA)
- Skin‑joint combo. About 30 % of psoriasis patients develop arthritis.
- Can be axial (spine involvement) or peripheral (dactylitis—the “sausage finger”).
- Nail pitting or onycholysis is a tell‑tale sign.
Reactive Arthritis (ReA)
- Post‑infection flare—often after a GI bug (Salmonella, Shigella) or a sexually transmitted infection (Chlamydia).
- Triad: Urethritis, conjunctivitis, and arthritis (the classic “Reiter’s” syndrome).
- Usually self‑limited but can become chronic.
Enteropathic Arthritis
- IBD‑linked—either Crohn’s disease or ulcerative colitis.
- Joint symptoms may appear before gut symptoms, making diagnosis tricky.
- Peripheral pattern is common, but axial disease isn’t rare.
Undifferentiated Spondyloarthropathy (uSpA)
- The “in‑between” category. Patients meet SpA criteria but don’t fit neatly into the other boxes.
- Over time, many evolve into a defined subtype (often AS or PsA).
Common Mistakes / What Most People Get Wrong
-
Assuming all back pain is mechanical.
A 25‑year‑old with “sports injury” back pain that’s worse at night? Think SpA. -
Equating HLA‑B27 positivity with disease.
Up to 8 % of healthy people carry the gene. It’s a clue, not a diagnosis. -
Ignoring extra‑articular clues.
Missing a mild skin rash can lead you to label a patient’s arthritis as “idiopathic.” -
Relying on plain X‑rays alone.
Early sacroiliitis is often invisible on X‑ray; MRI is the gold standard for early detection Not complicated — just consistent.. -
Treating every SpA the same.
PsA with predominant skin disease may respond better to IL‑17 inhibitors, while pure axial AS often starts with a TNF blocker.
Practical Tips – What Actually Works
- Screen early. If a patient under 40 complains of chronic back pain, ask about morning stiffness, eye redness, skin lesions, and recent infections.
- Order an MRI of the sacroiliac joints when X‑ray is equivocal but suspicion is high.
- Check HLA‑B27 after you’ve gathered clinical clues—don’t use it as a first‑line screen.
- Tailor therapy to the dominant feature:
- Axial dominance: start with a TNF inhibitor (adalimumab, etanercept).
- Peripheral or skin‑dominant: consider IL‑17A blockers (secukinumab) or IL‑12/23 inhibitors (ustekinumab).
- Monitor extra‑articular sites regularly. A silent uveitis can cause permanent vision loss if missed.
- Educate patients about “red‑flag” symptoms—new eye pain, sudden bowel changes, or worsening stiffness—that warrant immediate review.
FAQ
Q: Can gout be a spondyloarthropathy?
A: No. Gout is a crystal‑induced arthritis. It can affect the foot or knee but doesn’t follow the SpA pattern of axial involvement or HLA‑B27 association Still holds up..
Q: Is osteoarthritis ever classified as a spondyloarthropathy?
A: Not unless there’s a coexisting SpA. Osteoarthritis is a wear‑and‑tear disease, while SpA is inflammatory Worth keeping that in mind..
Q: Do all patients with ankylosing spondylitis have HLA‑B27?
A: About 80‑90 % do, but a minority are HLA‑B27 negative and still meet clinical criteria.
Q: How soon after an infection can reactive arthritis appear?
A: Typically 1‑4 weeks after the triggering GI or genitourinary infection.
Q: Can a child develop a spondyloarthropathy?
A: Yes. Juvenile-onset ankylosing spondylitis and enthesitis‑related arthritis are recognized pediatric forms.
Bottom Line
Spondyloarthropathies aren’t a single disease—they’re a tightly knit family of inflammatory arthritis that love the spine, the entheses, and a few extra‑articular party tricks. The main players—ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, and undifferentiated spondyloarthropathy—share genetic and clinical threads that make them recognizably “SpA.”
Spotting them early, using the right imaging, and tailoring treatment to the dominant manifestation can keep patients from marching toward permanent joint damage. So the next time you hear “spondyloarthropathy,” you’ll know exactly which diseases are marching under that banner—and, more importantly, how to catch them before they march too far.
